FCER1G and brain neoplasm: To date, CD3ζ remains the preferred option for brain tumors due to its similarity to FcRγ, which mediates antibody-dependent phagocytosis effectively, and its extensive validation in CAR-T therapies, ensuring reliability in adapting CAR technology for MACs.69 Expanding research into alternative intracellular domains could enhance therapeutic options for brain tumor treatment by boosting either CAR-MAC phagocytic activity or M1 polarization.